Advertisement

Psychopharmacology

, Volume 107, Issue 2–3, pp 144–159 | Cite as

Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I

  • Martin Sarter
  • Jim Hagan
  • Paul Dudchenko
Reviews

Abstract

Preclinical efforts to detect and characterize potential cognition enhancers appear to have been dominated by a strategy of demonstrating a wide variety of apparently beneficial behavioral effects with little attention given to the specific psychological mechanisms underlying behavioral enhancement. In particular, the question of whether or not behavioral facilitation is based on relevant mnemonic mechanisms and is independent of the stimulus properties and/or the motivational and attentional components of a task is not often considered. As a result, an overwhelming number of compounds have failed to produce the clinical effects predicted for them on the basis of preclinical research. The available data suggest that a more successful approach requires deductive research strategies rather than the indiscriminate accumulation of apparently beneficial effects in a variety of behavioral tasks and animal models. The first step towards such an approach is a systematic and rigorous evaluation of the different aspects of validity for the models most frequently used in preclinical research. It is concluded that a combination of good construct validity and good face validity represents a necessary condition for screening tests with predictive validity, and that the most popular paradigms fail to fulfil these criteria. Future screening programs for cognition enhancers will probably be characterized by a depreciation of “fast and dirty tests” in favor of approaches focussing on the validity of the effects of potential cognition enhancers.

Key words

Nootropics Cognition enhancers Dementia Aging 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bagne CA, Pomara N, Crook T, Gershon S (1986) Alzheimer's disease: strategies for treatment and research. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer's disease. Mark Powley, Madison, pp 585–638Google Scholar
  2. Barnas C, Miller C, Gunther V, Fleischhacker W (1987) Treatment of alcohol organic mental disorder with piracetam. Progr Neuropsychopharmacol Biol Psychiatry 11:729–737CrossRefGoogle Scholar
  3. Barnes JM, Costall B, Coughlan J, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ, Onaivi ES, Tomkins DM, Tyers MB (1990) The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 35:955–962Google Scholar
  4. Barondes SH (1969) Cerebral protein synthesis inhibitors block long term memory. Int Rev Neurobiol 12:177–205Google Scholar
  5. Barraco RA, Stettner LJ (1976) Antibiotics and memory. Psychol Bull 2:242–302Google Scholar
  6. Bartus RT (1978) Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 9:833–836Google Scholar
  7. Bartus RT (1988) The need for common perspectives in the development and use of animal models for age-related cognitive and neurodegenerative disorders. Neurobiol Aging 9:445–451PubMedGoogle Scholar
  8. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417Google Scholar
  9. Beatty WW, Butters N, Janowski DS (1986) Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav Neural Biol 45:196–211Google Scholar
  10. Becker RE, Giacobini E (1988) Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects. Drug Dev Res 12:163–195CrossRefGoogle Scholar
  11. Beninger RJ (1989) Methods for determining the effects of drugs on learning. In: Boulton AA, Baker GB, Greenshaw AJ (eds) Neuromethods. Psychopharmacology, vol 13. Humana Press, Clifton, pp 623–685Google Scholar
  12. Biegon A, Greenberger V, Segal M (1986) Quantitative histochemistry of brain acetylcholinesterase and learning rate in the aged rat. Neurobiol Aging 7:215–217CrossRefPubMedGoogle Scholar
  13. Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN (1986) Muscarinic agonist therapy of Alzheimer's disease: a clinical trial of RS-86. Arch Neurol 43:659–661PubMedGoogle Scholar
  14. Byrne J, Arie T (1989) Tetrahydroaminoacridine (THA) in Alzheimer's disease. BMJ 298:845–846PubMedGoogle Scholar
  15. Caine ED (1980) Cholinomimetic treatment fails to improve memory disorders. N Engl J Med 303:585–586Google Scholar
  16. Caltagirone C, Gainotti C, Masullo O (1982) Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 16:247–249PubMedGoogle Scholar
  17. Chatelier G, Lacomblez L, et al (1990) Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer's type: a multicentre trial. BMJ 300:495–499PubMedGoogle Scholar
  18. Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F (1983) Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology 81:100–106Google Scholar
  19. Christie JE, Shering A, Ferguson J, Glem AIM (1981) Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50PubMedGoogle Scholar
  20. Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN (1991) Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology 41:570–574PubMedGoogle Scholar
  21. Collerton D (1986) Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19:1–28CrossRefPubMedGoogle Scholar
  22. Cumin R, Bandle EF, Gamzu E, Haefely, WE (1982) Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology 78:104–111Google Scholar
  23. Davidson M, Zemishlany Z, Mohs RC, Horvath TB, Powchik P, Blass JP, Davis KL (1988) 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry 23:485–490CrossRefPubMedGoogle Scholar
  24. Davis B, Andrewes D, Stargatt R, Ames D, Tuckwell V, Davis S (1990) Tetrahydroaminoacridine in Alzheimer's disease. Int J Geriat Psychiatry 5:317–321CrossRefGoogle Scholar
  25. Davis JW, Thomas RK, Adams HE (1971) Interactions of scopolamine and physostigmine with ECS and one trial learning. Physiol Behav 6:219–222Google Scholar
  26. Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB (1987) Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 144:468–471PubMedGoogle Scholar
  27. Deacon RMJ, Budhram P, Dawson D, Galliani G, Guy AP, Gardner CR (1990) Investigation of potential cognition enhancing properties of RU 33965, a benzodiazepine receptor partial inverse agonist. Psychopharmacology 101 [suppl]:45Google Scholar
  28. Dean RL, Bartus RT (1988) Behavioral models of aging in nonhuman primates. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology. Psychopharmacology of the aging nervous system, vol 20. Plenum Press, New York, pp 325–392Google Scholar
  29. Dekker JAM, Connor DJ, Thal LJ (1991) The role of cholinergic projections from the nucleus basalis in memory. Neurosci Biobehav Rev 15:299–317Google Scholar
  30. DeNoble VJ, Repetti SJ, Gelpke, LW, Wood LM, Keim KL (1986) Vincopetine: nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 24:1123–1128CrossRefPubMedGoogle Scholar
  31. Devanand DP, Sackeim HA, Brown RP, Mayeux R (1989) A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 46:854–857PubMedGoogle Scholar
  32. Dokla CPJ, Thal LJ (1988) Effect of cholinesterase inhibitors on Morris water task behavior following lesions of the nucleus basalis magnocellularis. Behav Neurosci 102:861–871CrossRefPubMedGoogle Scholar
  33. Dokla CPJ, Parker SC, Thal LJ (1989) Tetrahydroaminoacridine facilitates passive avoidance learning in rats with nucleus basalis magnocellularis lesions. Neuropharmacology 11:1279–1282CrossRefGoogle Scholar
  34. Duka T, Stephens DN, Krause W, Dorow R (1987) Human studies on the benzodiazepine receptor antagonist β-carboline ZK 93 426: preliminary observations on psychotropic activity. Psychopharmacology 93:421–427Google Scholar
  35. Duka T, Edelmann V, Schütt B, Dorow R (1988) β-Carboniles as tools in memory research: human data with the β-carboline ZK 93 426. In: Hindmarch I, Ott H (eds) Benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 246–260Google Scholar
  36. Duncan CP (1949) The retroactive effect of electroshock on learning. J Comp Physiol Psychol 42:32–44Google Scholar
  37. Essman WB (1971) Drug effects and learning and memory processes. Adv Pharmacol Chemother 9:241–330PubMedGoogle Scholar
  38. Fisher A, Brandeis R, Pittel Z, Karton I, Sapir M, Dachir S, Levy A, Heldman E (1989) (+/-)-cis-2-methyl-spiro (1,3-oxathiolane-5,3') guinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A treated rats. Neurosci Lett 102:325–331CrossRefPubMedGoogle Scholar
  39. Fitten LJ, Perryman KM, Gross PL, Fine H, Cummins J, Marshall C (1990) Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 147:239–242PubMedGoogle Scholar
  40. Flicker C, Serby M, Ferris SH (1990) Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100:243–250Google Scholar
  41. Flood JF, Cherkin A (1986) Scopolamine effects on memory retention in mice: A model for dementia? Behav Neural Biol 45:169–184CrossRefPubMedGoogle Scholar
  42. Flood JF, Vidal D, Bennett EL, Orme AE, Vasquez S, Jarvik ME (1978) Memory facilitation and anti-amnesic effects of corticosteroids. Pharmacol Biochem Behav 8:81–87Google Scholar
  43. Forsyth DR, Surmon DJ, Morgan RA, Wilcock GK (1989) Clinical experience with side effects of tacrine hydrochloride in Alzheimer's disease: a pilot study. Age Ageing 18:223–229PubMedGoogle Scholar
  44. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S (1989) Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 39:257–261PubMedGoogle Scholar
  45. Freedman LS, Judge ME, Quartermain D (1982) Effect of cycloheximide, a protein synthesis inhibitor, on mouse brain catecholamine biochemistry. Pharmacol Biochem Behav 17:187–191Google Scholar
  46. Gash DM, Thomas GH (1983) What is the importance of vasopressin in memory processes? TINS 6:197–198Google Scholar
  47. Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, Tesfaye Y, Saint-Martin M, Bacher Y, Carrier L, Charbonneau R, Clarfield AM, Collier B, Dastoor D, Gauthier L, Germain M, Kissel C, Krieger M, Kushnir S, Masson H, Morin J, Nair V, Neirink L, Suissa S (1990) Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate stage Alzheimer's disease. N Engl J Med 322:1272–1276PubMedGoogle Scholar
  48. Gauthier S, Bouchard R, Bacher Y, Bailey P, Bergman H, Carrier L, Carbaonneau R, Clarfield M, Bollier B, Dastorr D, Gauthier L, Germain M, Kissel M, Krieger M, Kushnir S, Lamontagne A, Morin J, Nair NPV, Neirinck L, Ratner J, St-Martin M, Suissa S, Tesfaye Y (1989) Progress report on the Canadian multicentre trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease. Can J Neurol Sci 16:543–546PubMedGoogle Scholar
  49. Geula C, Mesulam MM (1989) Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience 33:469–481CrossRefPubMedGoogle Scholar
  50. Growdon JH, Corkin S, Huff FJ, Rosen TJ (1986) Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7:269–276CrossRefPubMedGoogle Scholar
  51. Hagan JJ, Morris RGM (1988) The cholinergic hypothesis of memory: a review of animal experiments. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology. Psychopharmacology of the aging nervous system, vol 20. Plenum Press, New York, pp 237–232Google Scholar
  52. Hagan JJ, Jansen JHM, Broekkamp CLE (1989) Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics. Psychopharmacology 98:347–356Google Scholar
  53. Hagan JJ, Jansen JHM, Nefkens FEW, de Boer T (1990) Therapeutic effect of THA on hemicholinium-3 induced learning impairment is dependent of serotonergic and noradrenergic systems. Psychopharmacology 101:376–383Google Scholar
  54. Handelmann GE, Nevins ME, Mueller LL, Arnolde, SM, Cordi AA (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnesic rodents. Pharmacol Biochem Behav 34:823–828Google Scholar
  55. Harbaugh RE, Reeder TM, Senter HJ, Knopman DS, Raskin DS, Pirozzolo F, Chang-Chui H, Shetter AG, Bakay RAE et al. (1989) Intracerebroventricular bethanecol chloride infusion in Alzheimer's disease. J Neurosurg 71:481–486PubMedGoogle Scholar
  56. Haroutunian V, Kanof PD, Davis K (1985) Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sci 37:945–952CrossRefPubMedGoogle Scholar
  57. Haroutunian V, Kanof PD, Tsuboyama GK, Campbell GA, Davis KL (1986) Animal models of Alzheimer's disease: behavior, pharmacology, transplants. Can J Neurol Sci 13:385–393PubMedGoogle Scholar
  58. Haroutunian V, Kanof PD, Tsuboyama GK, Campbell GA, Davis KL (1990a) Restoration of cholinomimetic activity by clonidine in cholinergic plus adrenergic lesioned rats. Brain Res 507:261–266CrossRefPubMedGoogle Scholar
  59. Haroutunian V, Mantin R, Kanof PD (1990b) Frontal cortex as the site of action of physostigmine in nBM lesioned rats. Physiol Behav 47:203–206Google Scholar
  60. Heise GA (1984) Behavioral methods for measuring effects of drugs on learning and memory in animals. Med Res Rev 4:534–558Google Scholar
  61. Henderson VW, Roberts E, Wimer C, Bardolph EL, Chui HC, Damasio AR, Eslinger PJ, Goldstein MF, Schneider LS, Teng EL, Tune LE, Weiner LP, Whitehouse PJ (1989) Multicenter trial of naloxone in Alzheimer's disease. Ann Neurol 25:404–406CrossRefPubMedGoogle Scholar
  62. Hinde RA (1976) The use of differences and similarities in comparative psychopathology. In: Serban G, Kling A (eds) Animal models in human psychobiology. Plenum Press, New York, pp 187–202Google Scholar
  63. Hock FJ, McGaugh JL (1985) Enhancing effects of Hoe 175 on memory in mice. Psychopharmacology 86:114–117Google Scholar
  64. Hock FJ, Gerhards HJ, Wiemer G, Stechl J, Rüger W, Urbach H (1989) Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents. Eur J Pharmacol 171:79–85CrossRefPubMedGoogle Scholar
  65. Hodges H, Ribeiro AM, Gray JA, Marchbanks RM (1990) Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats. Pharmacol Biochem Behav 36:291–298Google Scholar
  66. Hoffmeister F, Benz U, Heise A, Krause HP, Neuser V (1982) Behavioral effects of nimodipine in animals. Drug Res 32:347–360Google Scholar
  67. Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, Davis KL (1987) RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 22:1067–1078CrossRefPubMedGoogle Scholar
  68. Höhmann CF, Antuono P, Coyle JT (1988) Basal forebrain cholinergic neurons and Alzheimer's disease. In: Iversen LI, Snyder SH, Iversen SD (eds) Handbook of psychopharmacology. Plenum Press, New York, pp 69–106Google Scholar
  69. Huff FJ, Mickel SF, Corkin S, Growdon JH (1988) Cognitive functions affected by scopolamine in Alzheimer's disease and normal aging. Drug Dev Res 12:271–278CrossRefGoogle Scholar
  70. Izquierdo I (1989) Different forms of post-training memory processing. Behav Neural Biol 51:171–202Google Scholar
  71. Janssen PAJ (1964) Screening tests and prediction from animals to man. In: Steinberg H (ed) Animal behavior and drug action. Little, Brown, Boston, pp 264–268Google Scholar
  72. Jensen LH, Stephens DN, Sarter M, Petersen EN (1987) Bidirectional effects of β-carbolines and benzodiazepines on memory processes. Brain Res Bull 19:359–364CrossRefPubMedGoogle Scholar
  73. Jones DNC, Carey GJ, Costall B, Domeney AM, Gerrard PA, Naylor RJ, Tyers MB (1990) Arecoline and ondansetron reverse scopolamine-induced deficits in an object discrimination task in the marmoset. Psychopharmacology 101 [suppl]:99Google Scholar
  74. Kameyama T, Nabeshima T, Noda Y (1986) Cholinergic modulation of memory for step down type passive avoidance task in mice. Res Communic Psychol Psychiatr Behav 2:193–206Google Scholar
  75. Kawajiri S, Sakurai T, Ojima H, Hatanaka S, Yamasaki T, Kojima H, Akashi A (1988) Effect of DM-9384, a new pyrrolidone derivative, on learning behavior and cerebral choline acetyltransferase activity in rats. Psychopharmacology 96 [suppl]:306Google Scholar
  76. Kelly PH, Enz A, Amstutz R (1990) Effects of cholinergic agents in a new two-trail swim test of exploration and memory formation. Psychopharmacology 102 [suppl]:104CrossRefGoogle Scholar
  77. Kolb B, Whishaw IQ (1990) Fundamentals of human neuropsychology. W.H. Freeman, New YorkGoogle Scholar
  78. Kopelman MD, Corn TH (1988) Cholinergic “blockade” as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 111:1079–1110PubMedGoogle Scholar
  79. Kwo-On-Yuen PF, Mandel R, Chen AD, Thal LJ (1990) Tetrahydroaminoacridine improves the spatial deficit produced by nucleus basalis lesions in rats. Expl Neurol 108:221–228CrossRefGoogle Scholar
  80. Lal H, Kumar B, Forster MJ (1988) Enhancement of learning and memory in mice by a benzodiazepine receptor antagonist. FASEB J 2:2707–2711PubMedGoogle Scholar
  81. Levin ED (1988) Scopolamine interactions with D1 and D2 antagonists on radial-arm maze performance in rats. Behav Neural Biol 50:240–245CrossRefPubMedGoogle Scholar
  82. Maho C, Dutrieux G, Ammassari-Teule M (1988) Parallel modifications of spatial memory performance, exploration patterns and hippocampal theta rhythms in fornix damaged rats: reversal by oxotremorine. Behav Neurosci 102:610–604Google Scholar
  83. Mandel RJ, Thal LJ (1988) Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats. Psychopharmacology 96:421–425Google Scholar
  84. Markstein R (1989) Pharmacological approaches in the treatment of senile dementia. Eur Neurol 29:33–41Google Scholar
  85. Martinez JL, Jensen RA, McGaugh JL (1981) Attenuation of experimentally-induced amnesia. Prog Neurobiol 16:155–186CrossRefPubMedGoogle Scholar
  86. Mastropaolo J, Nadi NS, Ostrowski NL, Crawley JN (1988) Galanin antagonizes acetylcholine on a memory task in basal forebrain lesioned rats. Proc Natl Acad Sci USA 85:9841–9845PubMedGoogle Scholar
  87. McGaugh JL (1989a) Dissociating learning and performance: drug and hormone enhancement of memory storage. Brain Res Bull 23:329–345CrossRefGoogle Scholar
  88. McGaugh JL (1989b) Involvement of hormonal and neuromodulatory systems in the regulation of memory storage. Annu Rev Neurosci 12:255–287CrossRefPubMedGoogle Scholar
  89. McGaugh JL, Gold PE (1976) Modulation of memory by electrical stimulation of the brain. In: Rosenzweig MR, Bennett EL (eds) Neural mechanisms of learning and memory. MIT Press, Cambridge, pp 549–560Google Scholar
  90. McGurk SR, Levin ED, Butcher LL (1988) Cholinergic-dopaminergic interactions in radial-arm maze performance. Behav Neural Biol 49:234–239Google Scholar
  91. McKinney WT, Bunney WE (1969) Animal model of depression: review of evidence and implications for research. Arch Gen Psychiatry 21:240–248PubMedGoogle Scholar
  92. Miyamoto M, Narumi S, Nagaoka A, Coyle JT (1989) Effects of continuous infusion of cholinergic drugs on memory impairment in in rats with basal forebrain lesions. J Pharmacol Exp Ther 248:825–835PubMedGoogle Scholar
  93. Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, Clauss JJ, Fedio P, Chase TN (1989) Clonidine treatment of Alzheimer's disease. Arch Neurol 46:376–378PubMedGoogle Scholar
  94. Molchan SE, Mellow AM, Lawlor BA, Weingartner HJ, Cohen RM, Cohen MR, Sunderland T (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 100:84–89Google Scholar
  95. Molloy DW, Cape RDT (1989) Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. Neurobiol Aging 10:199–204CrossRefPubMedGoogle Scholar
  96. Moos WH, Davis RE, Schwartz RD, Gamzu EK (1988) Cognition activators. Med Res Rev 8:353–391PubMedGoogle Scholar
  97. Mouradian MM, Mohr E, Williams JA, Chase TN (1988) No response to high dose muscarinic agonist therapy in Alzheimer's disease. Neurology 38:606–608PubMedGoogle Scholar
  98. Murray CL, Fibiger HC (1985) Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine. Neuroscience 14:1025–1032CrossRefPubMedGoogle Scholar
  99. Murray CL, Fibiger HC (1986) Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis. Behav Neurosci 100:23–32CrossRefPubMedGoogle Scholar
  100. Nabeshima T, Yoshida S, Kameyama T (1988a) Effects of the novel compound NIK-247 on impairment of passive avoidance response in mice. Eur J Pharmacol 154:263–269CrossRefPubMedGoogle Scholar
  101. Nabeshima T, Noda Y, Kameyama T (1988b) GABAergic modulation of memory with regard to passive avoidance and conditioned suppression tasks in mice. Psychopharmacology 94:69–73Google Scholar
  102. Nabeshima T, Noda Y, Tohyama K, Ithoh J, Kameyama T (1990a) Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 178:143–149CrossRefPubMedGoogle Scholar
  103. Nabeshima T, Tohyama K, Ichihara K, Kameyama T (1990c) Attenuation of benzodiazepine-induced passive avoidance deficit by post-training administration of muscimol: interaction with the cholinergic neuronal system. Eur J Pharmacol 182:555–560CrossRefPubMedGoogle Scholar
  104. Nabeshima T, Tohyama K, Kameyama T (1990b) Effects of DM-9384, a pyrrolidone derivative, on alcohol- and chlordiazepoxide-induced amnesia in mice. Pharmacol Biochem Behav 36:233–236Google Scholar
  105. Nabeshima T, Tohyama K, Murase K, Ishihara S, Kameyama T, Yamsaki T, Hatanaka S, Kojima H, Sakurai T, Takasu Y, Shiotani T (1991) Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and muscarinic rerceptors induced by cycloheximide. J Pharmacol Exp Ther 257:271–275PubMedGoogle Scholar
  106. Nakahara N, Iga Y, Saito Y, Mizobe F, Kawanishi G (1989) Beneficial effects of FKS-508 (AF102B), a selective M1 agonist, on impaired working memory in AF64A treated rats. Jpn J Pharmacol 51:539–547PubMedGoogle Scholar
  107. Nakahara N, Fujise N, Kawanishi G, Mizobe F (1990) Central muscarinic activities of an M1-selective agonist: preferential effect on reversal of amnesia. Brain Res 507:172–175CrossRefPubMedGoogle Scholar
  108. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95:171–175Google Scholar
  109. Nicholson CD (1990) Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101:147–159Google Scholar
  110. Nyback H, Nyman H, Nordgren I, Lindstrom B (1988) Preliminary experiences and results with THA for the amelioration of symptoms of Alzheimer's disease. In: Giacobini E, Becker R (eds) Current research in Alzheimer's therapy. Taylor and Francis, New York, pp 231–236Google Scholar
  111. Okazaki Y, Natori K, Irie T, Katsube J (1990) Effect of a novel CNS-selective cholinesterase inhibitor, SM-10888, on habituation and passive avoidance responses in mice. Jpn J Pharmacol 53:211–220PubMedGoogle Scholar
  112. Palmer AM, Francis PT, Benton JS, Sims NR, Mann DMA, Neary D, Snowdon JS, Bowen DM (1987a) Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 48:8–15PubMedGoogle Scholar
  113. Palmer AM, Francis PT, Bowen DM, Benton JS, Neary D, Mann DMA, Snowdon JS (1987b) Catecholaminergic neurons assessed ante-mortem in Alzheimer's disease. Brain Res 414:365–375CrossRefPubMedGoogle Scholar
  114. Parsons DS, Peagler A, Barlow TS, Harrell LE (1987) Failure of chronic physostigmine to ameliorate working memory deficits after medial septal lesions. Exp Neurol 96:456–461CrossRefPubMedGoogle Scholar
  115. Perry EK (1988) The cholinergic hypothesis-ten years on. Br Med Bull 42:63–69Google Scholar
  116. Piercey MF, Vogelsang GD, Franklin SR, Tang AH (1987) Reversal of scopolamine-induced amnesia and alterations in energy metabolism by the nootropic piracetam: implications regarding identification of brain structures involved in consolidation of memory traces. Brain Res 424:1–9CrossRefPubMedGoogle Scholar
  117. Pontecorvo MJ, Evans HL (1985) Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons. Pharmacol Biochem Behav 22:745–752Google Scholar
  118. Porsolt RD (1989) The silent epidemic: the search for treatment of age-related memory impairment. TIPS 10:3–6PubMedGoogle Scholar
  119. Poschel BPH (1988) New pharmacological perspectives on nootropic drugs. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology. Psychopharmacology of the aging nervous system, vol 20. Plenum Press, New York, pp 437–469Google Scholar
  120. Procter AW, Lowe SL, Palmer AM, Francis PT, Esiri MM, Stratmann GC, Naijlerahim A, Patel AJ, Hunt A, Bowen DM (1988) Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 84:125–140CrossRefPubMedGoogle Scholar
  121. Quartermain D, Altman HJ (1982) Facilitation of retrieval byd-amphetamine following anisomycin-induced amnesia. Physiol Psychol 10:283–292Google Scholar
  122. Randt CT, Judge ME, Bonnet KA, Quartermain D (1982) Brain cyclic AMP and memory in mice. Pharmacol Biochem Behav 17:677–680Google Scholar
  123. Ridely RM, Baker HF, Drewett B, Johnson JA (1985) Effects of ibotenic acid lesions of the basal forebrain on serial reversal learning in marmosets. Psychopharmacology 86:438–443Google Scholar
  124. Ridely RM, Murray TK, Johnson JA, Baker HF (1986) Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: modification cholinergic drugs. Brain Res 376:108–116CrossRefPubMedGoogle Scholar
  125. Ridely RM, Baker HF, Drewett B (1987) Effects of arecoline and pilocarpine on learning ability with marmosets pretreated with hemicholinium-3. Psychopharmacology 91:512–514Google Scholar
  126. Ridely RM, Samson NA Baker HF, Johnson JA (1988) Visuospatial learning impairment following lesion of the cholinergic projection to the hippocampus. Brain Res 456:71–87CrossRefPubMedGoogle Scholar
  127. Riekkinen P, Sirvio J, Riekkinen P (1990) The effects of THA on medial septal lesion induced memory deficits. Pharmacol Biochem Behav 36:237–241Google Scholar
  128. Robbins TW (1988) Arresting memory decline. Nature 336:207–208CrossRefPubMedGoogle Scholar
  129. Robinson DS, Kurtz NM (1986) A scientific and pharmaceutical industry perspective. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies of Alzheimer's disease. Mark Powley, Madison, pp 655–670Google Scholar
  130. Rogers DC, Ballard TM, Hunter AJ, Hill RG (1990) Comparison of the effects of scopolamine and tacrine in the Morris water maze and delayed non-matching to sample task. Psychopharmacology 101 [suppl]:186Google Scholar
  131. Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD (1989) Comparison of the effects of four cholinomimetics agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 99:189–195Google Scholar
  132. Rush DK (1986) Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone. Psychopharmacology 89:296–300Google Scholar
  133. Russell RW (1964) Extrapolation from animals to man. In: Steinberg H (ed) Animal behavior and drug action. Churchill, London, pp 410–418Google Scholar
  134. Sahakian BJ, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797–800PubMedGoogle Scholar
  135. Sahgal A (1984) A critique of the vasopressin-memory hypothesis. Psychopharmacology 83:215–228Google Scholar
  136. Sansone M, Castellano C, Battaglia M, Ammassari-Teule M (1990) Oxiracetam prevents mecamylamide-induced impairment of active, but not passive, avoidance learning in mice. Pharmacol Biochem Behav 36:389–392Google Scholar
  137. Santucci AC, Kanof PD, Haroutunian V (1989) Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology 99:70–74Google Scholar
  138. Sara SJ (1980) Memory retrieval deficits: alleviation by etiracetam, a nootropic drug. Psychopharmacology 68:235–241Google Scholar
  139. Sarter M, Steckler T (1989) Spontaneous exploration of a 6-arm radial tunnel maze by basal forebrain lesioned rats: effects of the benzodiazepine receptor antagonist β-carboline ZK 93 426. Psychopharmacology 98:193–202Google Scholar
  140. Sarter M, Stephens DN (1988) β-carbolines as tools in memory research: animal data and speculations. In: Hindmarch I, Ott H (eds) Benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 230–245Google Scholar
  141. Sarter M, Stephens DN (1989) Disinhibitory properties of β-carboline antagonists of benzodiazepine receptors: a possible therapeutic approach for senile dementia? Biochem Trans 17:81–83Google Scholar
  142. Sarter M, Bodewitz G, Stephens DN (1988) Attenuation of the scopolamine-induced impairment in spontaneous alternation behavior by antagonist but not inverse agonist and agonist β-carbolines. Psychopharmacology 94:491–495Google Scholar
  143. Sarter M, Bruno JP, Dudchenko P (1990) Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification. Psychopharmacology 101:1–17Google Scholar
  144. Schindler U, Rush DK, Fielding S (1984) Nootropic drugs: Animal models for studying effects on cognition. Drug Dev Res 4:567–576CrossRefGoogle Scholar
  145. Shutske GM, Pierrat FA, Cornfeldt ML, Szewczak MR, Huger FP, Bores GM, Haroutunian V, Davis KL (1988) (+/-)-9-amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity. J Med Chem 31:1278–1279CrossRefPubMedGoogle Scholar
  146. Spanis CW, Squire LR (1978) Elevation of brain tyrosine by hibitors of protein synthesis is not responsible for their amnesic effect. Brain Res 139:384–388CrossRefPubMedGoogle Scholar
  147. Spear NE, Miller JS, Jagielo JA (1990) Animal memory and learning. Annu Rev Psychol 41:169–211CrossRefPubMedGoogle Scholar
  148. Spignoli G, Pepeu G (1987) Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav 27:491–495Google Scholar
  149. Squire LR, Slater PC, Miller PL (1975) Retrograde amnesia: temporal gradient in very long-term memory following electroconvulsive therapy. Science 187:77–79PubMedGoogle Scholar
  150. Stephens DN, Sarter M (1988) Bidirectional nature of benzodiazepine receptor ligands extends to effects in vigilance. In: Hindmarch I, Ott H (eds) Benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 205–217Google Scholar
  151. Stone WS, Croul CE, Gold PE (1988) Attenuation of scopolamine-induced amnesia in mice. Psychopharmacology 96:417–420Google Scholar
  152. Strong R, Hicks P, Hsu L, Bartus RT, Enna SJ (1980) Age-related alterations in the rodent brain cholinergic system and behavior. Neurobiol Aging 1:59–63CrossRefPubMedGoogle Scholar
  153. Summers WK, Viesselamn JO, Marsh GM, Candelora K (1981) Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry 16:145–153PubMedGoogle Scholar
  154. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 315:1241–1245PubMedGoogle Scholar
  155. Sweeney JE, Höhman CF, Moran TH, Coyle JT (1988) A long acting cholinestrase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 31:141–147CrossRefPubMedGoogle Scholar
  156. Sweeney JE, Bachman ES, Coyle JT (1990) Effects of different doses of galanthamine, a long acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology 102:191–200Google Scholar
  157. Takashima A, Itoh S (1988) Effect of V-9-M, a peptide fragment derived from procholecystokinin, on memory processes in the rat. Can J Physiol Pharmacol 67:228–231Google Scholar
  158. Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H (1988) Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 45:901–905PubMedGoogle Scholar
  159. Thal LJ, Dokla CPJ, Armstrong DM (1988) Nucleus basalis magnocellularis lesions: lack of biochemical and immunocytochemical recovery and affect of cholinesterase inhibitors on passive avoidance. Behav Neurosci 102:852–860CrossRefPubMedGoogle Scholar
  160. Thompson TL, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byny RL (1990) Lack of hydergine in patients with Alzheimer's disease. N Engl J Med 323:445–458PubMedGoogle Scholar
  161. Tilson HA, McLamb RL, Shaw S, Rogers BC, Pediaditakis P, Cook L (1988) Radial-arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents. Brain Res 438:83–94CrossRefPubMedGoogle Scholar
  162. Tobe A, Egawa M, Nagai R (1983) Effect of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016) on the scopolamine-induced deficit of spontaneous alternation behavior in rats. Jpn J Pharmacol 33:775–784PubMedGoogle Scholar
  163. Ueki A, Miyoshi K (1989) Effects of cholinergic drugs on learning impairment in ventral globus pallidus lesioned rats. J Neurol Sci 90:1–21CrossRefPubMedGoogle Scholar
  164. Warburton DM, Wesnes K (1984) Drugs as research tools in psychology: cholinergic drugs and information processing. Neuropsychobiology 11:121–132PubMedGoogle Scholar
  165. Wettstein A, Spiegel R (1984) Clinical trials with the cholinergic drug RS 86 in Alzheimer disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 84:572–573Google Scholar
  166. Willner P (1984) The validity of animal models of depression. Psychopharmacology 83:1–16Google Scholar
  167. Willner P (1986) Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Progr Neuropsychopharmacol Biol Psychiatry 10:677–690CrossRefGoogle Scholar
  168. Wolters ECh, Riekkinen P, Lowenthal A, Van der Plaats JJ, Zwart JMT, Sennef C (1990) DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial. Neurology 40:1099–1101PubMedGoogle Scholar
  169. Yamamoto M, Shimizu M (1988) Effects of a new TRH analogue, YM-14673 on a passive avoidance test as a possible criterion of improvement in cognitive disturbance in rodents. Arch Pharmacol 338:262–267CrossRefGoogle Scholar
  170. Yamazaki N, Kato K, Kurihara E, Nagaoka A (1991) Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats. Psychopharmacology 103:215–222Google Scholar
  171. Zerbib R, Laborit H (1990) Chronic stress and memory: implication of the central cholinergic system. Pharmacol Biochem Behav 36:897–900Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Martin Sarter
    • 1
  • Jim Hagan
    • 1
  • Paul Dudchenko
    • 1
  1. 1.Department of PsychologyThe Ohio State UniversityColumbusUSA

Personalised recommendations